argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110).

The upfront payment comprises $300 million in cash from the Johnson & Johnson (NYSE:JNJ) unit, plus $200 million in equity through the sale of 1.8 million shares at

Read the full 526 word article

User Sign In